Paper Details

  1. Home
  2. Paper Details

Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.

Author: FindlingRobert L, FrazierJean A, HamerRobert M, HlastalaStefanie, JohnsonJacqueline L, KaufmanEmily Michael, LiebermanJeffrey A, LinglerJacqui, MaloneyAnn E, McClellanJon, McNamaraNora K, NoyesNancy, PiersonLeslie, PugliaMadeline, RitzLouise, SikichLinmarie, VitielloBenedetto

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

In a long-term study of three antipsychotics in early-onset schizophrenia spectrum disorders, only 12% of participants remained on their original treatment after 52 weeks. No drug showed superior efficacy, and all were associated with adverse effects, including weight gain. Further research is needed to develop more effective and tolerable treatments for this population.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. METHOD: Patients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20494268

データ提供：米国国立医学図書館（NLM）

The Challenges of Treating Early-Onset Schizophrenia Spectrum Disorders

Imagine a desert of the mind, where thoughts are often distorted and reality can be difficult to grasp. This is the reality for many young people with early-onset schizophrenia spectrum disorders. This research delves into the challenges of treating these complex conditions, exploring the long-term safety and efficacy of three antipsychotics: olanzapine, risperidone, and molindone.

A Difficult Path to Treatment

The results of this study highlight the difficult reality of treating early-onset schizophrenia spectrum disorders. The study found that only [12%] of youths with these conditions continued on their originally randomized treatment at 52 weeks. This suggests that finding effective and tolerable treatments for these conditions is a challenging task, like navigating a vast and shifting desert landscape.

Navigating the Treatment Landscape

This research underscores the need for more effective and safer treatments for young people with early-onset schizophrenia spectrum disorders. Understanding the unique challenges faced by this population, including the potential side effects of medications, is essential for creating personalized treatment plans. Further research is necessary to find solutions that can provide lasting relief and improve the quality of life for these individuals.

Dr.Camel's Conclusion

This study reminds us that treating early-onset schizophrenia spectrum disorders is like navigating a desert of the mind. It requires patience, persistence, and a deep understanding of the unique challenges faced by young people with these conditions. Continued research is crucial to find more effective and tolerable treatments that can bring these individuals out of the desert and into a brighter future.

Date :
  1. Date Completed 2010-12-28
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20494268

DOI: Digital Object Identifier

NIHMS192565

Related Literature

Article Analysis
・Side Effects of molindone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.